Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx

Aún no traducido Aún no traducido
Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2005
This is for a randomized clinical trial (RCT) to determine if the combined use of interferon beta-1a (IFN) and glatiramer acetate (GA) is a measurably better therapy than either agent used individually in patients with relapsing-remitting (RR) multiple sclerosis (MS).
Epistemonikos ID: 37142074252efcb277b1352d6f416c84aea683b5
First added on: Mar 30, 2022